Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript

Puma Biotechnology's investment case is defined by a stark contrast between its structurally high gross margins, averaging ~75%, and its volatile revenue trajectory, which has swung from a 32.4% decline to a 27.7% surge in recent quarters.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.15+66.7% vs $0.09 | $54M-5.9% vs $58M |
Q3 2026 Aug 6, 2026 | $0.19+375.0% vs $0.04 | $57M+6.6% vs $53M |
Q2 2026 May 7, 2026 | -$0.04+69.2% vs -$0.13 | $45M+6.7% vs $42M |
Q1 2026 Feb 26, 2026 | $0.29+20.8% vs $0.24 | $60M-12.7% vs $69M |
Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript

Puma Biotechnology NASDAQ: PBYI reported third-quarter 2026 revenue of $55.1 million and raised its full-year net income forecast, even as it lowered its outlook for royalties and narrowed its sales guidance for breast cancer drug NERLYNX.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced its third quarter earnings on Nov. 5 and followed with a conference call to provide a corporate update.
LOS ANGELES--(BUSINESS WIRE)--Puma biotechnology reported that it granted inducement awards in October 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Benchmark PBYI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Puma Biotechnology, Inc. (PBYI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.22 | $367.49M | 16.06 | -0.91% | 10.3% | 24.04% | — | |
| $15.76 | $1.98B | -4.51 | -4.26% | -445% | -90.04% | — | |
| $66.12 | $10.12B | 97.21 | 87.32% | 11.81% | 17.62% | — | |
| $60.23 | $5B | -47.44 | 114.51% | -9.17% | — | — | |
| $17.83 | $3.05B | 8.64 | 11.87% | 30.13% | 28.03% | — | |
| $68.29 | $17.17B | 19.73 | 6.98% | 35.45% | 45.54% | — |
Puma Biotechnology, Inc. (PBYI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Puma Biotechnology, Inc. (PBYI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 16, 2026·SEC
May 7, 2026·SEC
Get notified when PBYI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Puma Biotechnology, Inc. (PBYI) stock FAQ — growth, dividends, profitability & financials explained
Puma Biotechnology, Inc. (PBYI) reported $231.9M in revenue over the trailing twelve months. Revenue was $228.4M in fiscal year 2025.
Puma Biotechnology, Inc. (PBYI) grew revenue by 9.4% over the trailing twelve months, compared with the twelve months before.
Yes. Puma Biotechnology, Inc. (PBYI) earned $23.9M in net income over the trailing twelve months (a 10.3% net margin).
Puma Biotechnology, Inc. (PBYI) had a return on equity (ROE) of 24.0% over the trailing twelve months. That is well above the market's typical 10-15%.
Puma Biotechnology, Inc. (PBYI) generated $14.5M in free cash flow over the trailing twelve months.